Skip to main content

Advertisement

SpringerLink
Log in

Adverse Effects Reported and Insights Following Sinopharm COVID-19 Vaccination

  • Published:
Current Microbiology Aims and scope Submit manuscript

Abstract

Vaccines are promising strategies for controlling COVID-19; however, COVID-19 vaccine side effects play a central role in public confidence in the vaccine and its uptake process. This study aimed to provide evidence on the post-vaccination early side effects of the BBIBP-CorV (Sinopharm) vaccine. This cross-sectional survey-based study was conducted between November 2021 and January 2022 among recipients of the BBIBP-CorV vaccine, using a questionnaire-based survey. Our final sample consisted of 657 participants, including 392 women. Among the study cases, only 103 (15.7%) participants received one dose of vaccine, and the rest received both doses (N = 554, 84.3%). Systemic symptoms (first dose: N = 187, both doses: N = 128) were the most commonly reported events after vaccination, and among them, injection site pain (first dose: 19.3%, both doses: 12.9%) was the most prevalent adverse effect. All reporting events were mild and resolved in less than 3 days without hospitalization. Among the participants, females and young people aged 35–65 were more prone to manifest side effects (N = 169, 53.3%) after the vaccine injection. Furthermore, our results revealed that the recipients who were suffering from underlying diseases, including diabetes, renal disorder, and respiratory illness, reported fewer adverse responses after vaccination in comparison with healthy individuals. Vaccination against SARS-CoV-2 may lead to some adverse reactions in recipients. However, the frequency of post-vaccination early side effects differed in people, but all responses were slight and temporary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

The authors declare that data supporting the findings of this study are available within the article.

References

  1. Sun J, He W-T, Wang L, Lai A, Ji X, Zhai X et al (2020) COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med 26(5):483–495

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Raoofi A, Takian A, Haghighi H, Rajizadeh A, Rezaei Z, Radmerikhi S et al (2021) COVID-19 and comparative health policy learning; the experience of 10 countries. Arch Iran Med 24(3):260–272. https://doi.org/10.34172/aim.2021.37

    Article  PubMed  Google Scholar 

  3. Güner HR, Hasanoğlu İ, Aktaş F (2020) COVID-19: prevention and control measures in community. Turk J Med Sci 50(9):571–577. https://doi.org/10.3906/sag-2004-146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395(10223):507–513. https://doi.org/10.1016/S0140-6736(20)30211-7

    Article  CAS  Google Scholar 

  5. Huang AT, Garcia-Carreras B, Hitchings MD, Yang B, Katzelnick LC, Rattigan SM et al (2020) A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. MedRxiv. https://doi.org/10.1101/2020.04.14.20065771

    Article  PubMed  PubMed Central  Google Scholar 

  6. Biswas N, Mustapha T, Khubchandani J, Price JH (2021) The nature and extent of COVID-19 vaccination hesitancy in healthcare workers. J Community Health 46(6):1244–1251. https://doi.org/10.1007/s10900-021-00984-3

    Article  PubMed  PubMed Central  Google Scholar 

  7. Murdin AD, Barreto L, Plotkin S (1996) Inactivated poliovirus vaccine: past and present experience. Vaccine 14(8):735–746. https://doi.org/10.1016/0264-410x(95)00211-i

    Article  CAS  PubMed  Google Scholar 

  8. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P (2009) Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 27(15):2114–2120. https://doi.org/10.1016/j.vaccine.2009.01.125

    Article  CAS  PubMed  Google Scholar 

  9. Houshmand B, Keyhan SO, Fallahi HR, Ramezanzade S, Sadeghi E, Yousefi P (2022) Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV (Sinopharm)? Maxillofac Plast Reconstr Surg 44(1):1–11. https://doi.org/10.1186/s40902-021-00330-6

    Article  Google Scholar 

  10. Sahraian MA, Ghadiri F, Azimi A, Moghadasi AN (2021) Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV. Vaccine 39(43):6347–6350. https://doi.org/10.1016/j.vaccine.2021.09.030

    Article  CAS  Google Scholar 

  11. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W et al (2020) Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182(3):713-721.e9. https://doi.org/10.1016/j.cell.2020.06.008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF et al (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 21(1):39–51. https://doi.org/10.1016/S1473-3099(20)30831-8

    Article  CAS  PubMed  Google Scholar 

  13. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z et al (2020) Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 324(10):951–960. https://doi.org/10.1001/jama.2020.15543

    Article  CAS  PubMed  Google Scholar 

  14. https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf. Accessed Apr 2021

  15. Mahmood A, Shujaat SA, Hayat M, Ijaz F, Habib S, Sadaqat W et al (2022) Acute adverse effects of vaccines against SARS-COV-2. Cureus. https://doi.org/10.7759/cureus.27379

    Article  PubMed  PubMed Central  Google Scholar 

  16. Thonginnetra S, Tawinprai K, Niemsorn K, Promsena P, Tandhansakul M, Kasemlawan N et al (2022) Safety after BBIBP-CorV (Sinopharm) COVID-19 vaccine in adolescents aged 10–17 years in Thailand. Vaccines 10(10):1765. https://doi.org/10.3390/vaccines10101765

    Article  PubMed  PubMed Central  Google Scholar 

  17. Moll MEC, Martínez AMS, Cisneros BT, Onofre JIG, Floriano GN, de León MB (2022) Extension and severity of self-reported side effects of seven COVID-19 vaccines in mexican population. Front Public Health. https://doi.org/10.3389/fpubh.2022.834744

    Article  Google Scholar 

  18. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P et al (2021) Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis 21(7):939–949. https://doi.org/10.1016/S1473-3099(21)00224-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Attash HM, Al-Obaidy LM, Al-Qazaz HK (2022) Which type of the promising COVID-19 vaccines produces minimal adverse effects? A retrospective cross-sectional study. Vaccines 10(2):186. https://doi.org/10.3390/vaccines10020186

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Magdy R, Khedr D, Yacoub O, Attia A, Abdelrahman MA, Mekkawy D (2022) Epidemiological aspects of headache after different types of COVID-19 vaccines: an online survey. Headache: J Head Face Pain 62(8):1046–1052. https://doi.org/10.1111/head.14374

    Article  Google Scholar 

  21. Hatmal MM, Al-Hatamleh MA, Olaimat AN, Mohamud R, Fawaz M, Kateeb ET et al (2022) Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: a large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors. Vaccines 10(3):366. https://doi.org/10.3390/vaccines10030366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Hatmal MM, Al-Hatamleh MA, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM et al (2021) Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines 9(6):556. https://doi.org/10.3390/vaccines9060556

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Boshra MS, Hussein RR, Mohsen M, Elberry AA, Altyar AE, Tammam M et al (2022) A battle against COVID-19: vaccine hesitancy and awareness with a comparative study between Sinopharm and AstraZeneca. Vaccines 10(2):292. https://doi.org/10.3390/vaccines10020292

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A et al (2021) Side effects reported by Jordanian healthcare workers who received COVID-19 vaccines. Vaccines 9(6):577. https://doi.org/10.3390/vaccines9060577

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Al-Zidan R, Darweesh O, Salah M, Bebane P, Ahmed H, Abdulrazzaq G et al (2023) Are some COVID-19 vaccines better than others regarding the short-term side effects? Ceska a Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti 72(1):45–54

    CAS  PubMed  Google Scholar 

  26. Possible side effects after getting a COVID-19 vaccine (2021). https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html. Accessed 29 Sept 2023

  27. Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT et al (2021) Safety of COVID-19 vaccines. J Med Virol 93(12):6588–6594. https://doi.org/10.1002/jmv.27214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO (2021) Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis 111:219–226. https://doi.org/10.1016/j.ijid.2021.08.013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M (2021) Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med 10(7):1428. https://doi.org/10.3390/jcm10071428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Almufty HB, Mohammed SA, Abdullah AM, Merza MA (2021) Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr: Clin Res Rev 15(5):102207. https://doi.org/10.1016/j.dsx.2021.102207

    Article  CAS  Google Scholar 

  31. Riad A, Sağıroğlu D, Üstün B, Pokorná A, Klugarová J, Attia S et al (2021) Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey. J Clin Med 10(12):2629. https://doi.org/10.3390/jcm10122629

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Klein SL, Jedlicka A, Pekosz A (2010) The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 10(5):338–349. https://doi.org/10.1016/S1473-3099(10)70049-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Mousavi SA, Ovaise G et al (2021) Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Sci Rep 11(1):1–8. https://doi.org/10.1038/s41598-021-00963-7

    Article  CAS  Google Scholar 

  34. Iguacel I, Maldonado AL, Ruiz-Cabello AL, Casaus M, Moreno LA, Martínez-Jarreta B (2021) Association between COVID-19 vaccine side effects and body mass index in Spain. Vaccines 9(11):1321. https://doi.org/10.3390/vaccines9111321

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Evidence Assessment (2021) Sinopharm/BBIBP COVID-19 vaccine. World Health Organization, Geneva

    Google Scholar 

  36. Amer FHI, Alzayyat R, Alzayyat N, Alomran S, Wafai S, Alabssi H et al (2022) Side effects of COVID-19 vaccines (Pfizer, AstraZeneca) in Saudi Arabia, Eastern Province. Cureus. https://doi.org/10.7759/cureus.27297

    Article  PubMed  PubMed Central  Google Scholar 

  37. Vasilev G, Kabakchieva P, Miteva D, Batselova H, Velikova T (2022) Effectiveness and safety of COVID-19 vaccines in patients with diabetes as a factor for vaccine hesitancy. World J Diabetes 13(9):738–751. https://doi.org/10.4239/wjd.v13.i9.738

    Article  PubMed  PubMed Central  Google Scholar 

  38. Boroumand AB, Forouhi M, Karimi F, Soltani Moghadam A, Ghanbari Naeini L, Kokabian P et al (2022) Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: a systematic review. Front Immunol. https://doi.org/10.3389/fimmu.2022.940357

    Article  PubMed  PubMed Central  Google Scholar 

  39. Zhou X, Lu H, Sang M, Qiu S, Yuan Y, Wu T et al (2023) Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes. Hum Vaccines Immunother. https://doi.org/10.1080/21645515.2023.2184754

    Article  Google Scholar 

  40. Seo YB, Baek JH, Lee J, Song JY, Lee JS, Cheong HJ et al (2015) Long-term immunogenicity and safety of a conventional influenza vaccine in patients with type 2 diabetes. Clin Vaccine Immunol 22(11):1160–1165. https://doi.org/10.1128/CVI.00288-15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Holt SG, Mahmoud S, Ahmed W, Acuna JM, Al Madani AK, Eltantawy I et al (2022) An analysis of antibody responses and clinical sequalae of the Sinopharm HB02 COVID19 vaccine in dialysis patients in the United Arab Emirates. Nephrology 27(3):260–268. https://doi.org/10.1111/nep.13980

    Article  CAS  PubMed  Google Scholar 

  42. Alirezaei A, Fazeli SA, Shafiei M, Miladipour A (2022) Efficacy of Sinopharm® COVID-19 vaccine in hemodialysis patients: a preliminary report. Iran J Kidney Dis 16(4):259

    PubMed  Google Scholar 

  43. Sanders J-SF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R et al (2022) The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation 106(4):821–834. https://doi.org/10.1097/TP.0000000000003983

    Article  CAS  PubMed  Google Scholar 

  44. Simon B, Rubey H, Treipl A, Gromann M, Hemedi B, Zehetmayer S et al (2021) Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dial Transpl 36(9):1709–1716. https://doi.org/10.1093/ndt/gfab179

    Article  CAS  Google Scholar 

  45. Babel N, Hugo C, Westhoff TH (2022) Vaccination in patients with kidney failure: lessons from COVID-19. Nat Rev Nephrol. https://doi.org/10.1038/s41581-022-00617-5

    Article  PubMed  PubMed Central  Google Scholar 

  46. Rincon-Arevalo H, Choi M, Stefanski A-L, Halleck F, Weber U, Szelinski F et al (2021) Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol 6(61):eabj1031. https://doi.org/10.1126/sciimmunol.abj1031

    Article  PubMed  Google Scholar 

  47. Bhat TA, Panzica L, Kalathil SG, Thanavala Y (2015) Immune dysfunction in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc 12(Supplement 2):S169–S175. https://doi.org/10.1513/AnnalsATS.201503-126AW

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kalathil SG, Lugade AA, Pradhan V, Miller A, Parameswaran GI, Sethi S et al (2014) T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 190(1):40–50. https://doi.org/10.1164/rccm.201312-2293OC

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R (2020) Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev 16(5):442. https://doi.org/10.2174/1573399815666191024085838

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study supported by Students Research Committee, Ardabil University of Medical Sciences. The authors thank the patients and healthy individuals for participating in this study. The authors also wish to acknowledge the assistance of the staff of Imam Khomeini Hospital, Ardabil, Iran.

Funding

This study was supported in part by Ardabil University of Medical Sciences (finance code 400000331).

Author information

Author notes

  1. Alireza Mohebbi and Majid Eterafi have contributed equally to this work.

Authors and Affiliations

  1. Students Research Committee, Ardabil University of Medical Sciences, Ardabil, Iran

    Alireza Mohebbi, Majid Eterafi, Reza Panahizadeh & Kimia Karimi

  2. School of Medicine and Allied Medical Sciences, Ardabil University of Medical Sciences, Ardabil, Iran

    Nasrin Fouladi

  3. Social Determinants of Health Research Center, Ardabil University of Medical Sciences, Ardabil, Iran

    Nasrin Fouladi

  4. Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran

    Majid Golizadeh & Elham Safarzadeh

  5. Department of Internal Medicine, Emam Khomeini Hospital, Ardabil University of Medical Sciences, Ardabil, Iran

    Shahram Habibzadeh

  6. Department of Microbiology, Parasitology, and Immunology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

    Elham Safarzadeh

Authors
  1. Alireza Mohebbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Majid Eterafi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nasrin Fouladi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Majid Golizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reza Panahizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shahram Habibzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kimia Karimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elham Safarzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AM, ME, and ES conceived and planned the study; AM, ME and KK carried out the experiment and collected available literature; ME, MG, RP, NF and ES prepared the manuscript, analyzed the statistical data and verified the accuracy of the tests.

Corresponding author

Correspondence to Elham Safarzadeh.

Ethics declarations

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Consent to Participate

All patients signed informed consent before any study-related procedures were performed.

Consent for Publication

The patients were informed of the purpose of this study and an informed written consent has been obtained from the patients to publish this paper.

Ethical Approval

This study was approved by the approved by the Ethics Committee of Ardabil University of Medical Sciences, Ardabil, Iran (IR.ARUMS.REC.1400.212).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohebbi, A., Eterafi, M., Fouladi, N. et al. Adverse Effects Reported and Insights Following Sinopharm COVID-19 Vaccination. Curr Microbiol 80, 377 (2023). https://doi.org/10.1007/s00284-023-03432-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00284-023-03432-8

Search

Navigation